Research progress in the role of dysregulated RNA m6A modification in breast cancer metastasis

doi:10.3877/cma.j.issn.2095-1221.2023.01.006

Abstract

Abstract:

Metastasis is an important cause of poor survival and prognosis of patients with breast cancer; however, our current knowledge of its underlying molecular mechanism is limited. RNA N⁶-methyladenosine (m⁶A) modification is a novel mechanism of epi-transcriptional regulation of gene expression at the posttranscriptional level that has attracted much attention in the past decade. Its important role in malignant biology such as breast cancer metastasis is emerging now. The m⁶A modification of specific RNA is dynamically regulated by the methyltransferase complex (MTC) and RNA demethylases such as fat mass and obesity-associated protein (FTO) . The biological function of RNA that has undergone the m⁶A modification depends on the interpretation of its ''reader'' protein. This review summarizes the latest research progress in the role of dysregulated various components of RNA m⁶A modification including m⁶A ''writers'', ''erasers'' and ''readers'' in breast cancer metastasis as well as their underlying molecular mechanisms. Meanwhile, the future directions of development of precise detection of dysregulated RNA m⁶A modification in breast cancer metastasis and new targeted therapy strategies based on novel molecular mechanisms are also prospected.

Key words: N⁶-methyladenosine (m⁶A), RNA m⁶A modification, Breast cancer, Tumor metastasis, Epitranscriptome

Yating Wu, Shenghang Zhang, Shuiliang Wang. Research progress in the role of dysregulated RNA m⁶A modification in breast cancer metastasis[J]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2023, 13(01): 45-52.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbygxbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-1221.2023.01.006

https://zhxbygxbzz.cma-cmc.com.cn/EN/Y2023/V13/I01/45

Figures/Tables 3

References 82

1	Thennavan A, Beca F, Xia Y, et al. Molecular analysis of TCGA breast cancer histologic types[J]. Cell Genom, 2021, 1(3):100067. doi: 10.1016/j.xgen.2021.100067.
2	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
3	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
4	Britt KL, Cuzick J, Phillips KA. Key steps for effective breast cancer prevention[J]. Nat Rev Cancer, 2020, 20(8):417-436.
5	Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets[J]. Semin Cancer Biol, 2020, 60:14-27.
6	Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis[J]. Science, 2011, 331(6024):1559-1564.
7	李卓林, 贾如雪, 吴亚婷, 等. 肿瘤转移的分子机制及靶向干预研究新进展[J/CD]. 中华细胞与干细胞杂志（电子版）, 2022, 12 (1):51-58.
8	Zhang B, Gu Y, Jiang G. Expression and prognostic characteristics of m⁶A RNA methylation regulators in breast cancer[J]. Front Genet, 2020, 11:604597.
9	Boccaletto P, Stefaniak F, Ray A, et al. MODOMICS: a database of RNA modification pathways. 2021 update[J]. Nucleic Acids Res, 2022, 50(D1):D231-D235.
10	Kan RL, Chen J, Sallam T. Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation[J]. Trends Genet, 2022, 38(2):182-193.
11	Wiener D, Schwartz S. The epitranscriptome beyond m6A[J]. Nat Rev Genet, 2021, 22(2):119-131.
12	Ping XL, Sun BF, Wang L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J]. Cell Res, 2014, 24(2):177-189.
13	Jia G, Fu Y, Zhao X, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J]. Nat Chem Biol, 2011, 7(12):885-887.
14	Zheng G, Dahl JA, Niu Y, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility[J]. Mol Cell, 2013, 49(1):18-29.
15	Roundtree IA, Evans ME, Pan T, et al. Dynamic RNA modifications in gene expression regulation[J]. Cell, 2017, 169(7):1187-1200.
16	Huang H, Weng H, Chen J. The biogenesis and precise control of RNA m⁶A methylation[J]. Trends Genet, 2020, 36(1):44-52.
17	Dominissini D, Moshitch-Moshkovitz S, Schwartz S, et al. Topology of the human and mouse m⁶A RNA methylomes revealed by m⁶A-seq[J]. Nature, 2012, 485(7397):201-206.
18	Deng LJ, Deng WQ, Fan SR, et al. m⁶A modification: recent advances, anticancer targeted drug discovery and beyond[J]. Mol Cancer, 2022, 21(1):52.doi: 10.1186/s12943-022-01510-2.
19	An Y, Duan H. The role of m⁶A RNA methylation in cancer metabolism[J]. Mol Cancer, 2022, 21(1):14.doi: 10.1186/s12943-022-01500-4.
20	Liu L, Li H, Hu D, et al. Insights into N6-methyladenosine and programmed cell death in cancer[J]. Mol Cancer, 2022, 21(1):32. doi: 10.1186/s12943-022-01508-w.
21	Liu Y, Zhu T, Jiang Y, et al. The key role of RNA modification in breast cancer[J]. Front Cell Dev Biol, 2022, 10:885133.doi: 10.3389/fcell.2022.885133.
22	Zheng F, Du F, Qian H, et al. Expression and clinical prognostic value of m⁶A RNA methylation modification in breast cancer[J]. Biomark Res, 2021, 9(1):28.doi: 10.1186/s40364-021-00285-w.
23	Tai J, Wang L, Guo H, et al. Prognostic implications of N6-methyladenosine RNA regulators in breast cancer[J]. Sci Rep, 2022, 12(1):1222. doi: 10.1038/s41598-022-05125-x.
24	Fang Z, Mei W, Qu C, et al. Role of m⁶A writers, erasers and readers in cancer[J]. Exp Hematol Oncol, 2022, 11(1):45.doi: 10.1186/s40164-022-00298-7.
25	Wang T, Kong S, Tao M, er al. The potential role of RNA N6-methyladenosine in cancer progression[J]. Mol Cancer, 2020, 19(1):88.doi: 10.1186/s12943-020-01204-7.
26	Zheng F, Du F, Zhao J, et al. The emerging role of RNA N6-methyladenosine methylation in breast cancer[J]. Biomark Res, 2021, 9(1):39.doi: 10.1186/s40364-021-00295-8.
27	Zhao C, Ling X, Xia Y, et al. The m6A methyltransferase METTL3 controls epithelial-mesenchymal transition, migration and invasion of breast cancer through the MALAT1/miR-26b/HMGA2 axis[J]. Cancer Cell Int, 2021, 21(1):441.doi: 10.1186/s12935-021-02113-5.
28	Chen F, Chen Z, Guan T, et al. N6-methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis[J]. Cancer Res, 2021, 81(11):2847-2860.
29	Ramamoorthi G, Kodumudi K, Gallen C, et al. Disseminated cancer cells in breast cancer: Mechanism of dissemination and dormancy and emerging insights on therapeutic opportunities[J]. Semin Cancer Biol, 2022, 78:78-89.
30	Xie J, Ba J, Zhang M, et al. The m⁶A methyltransferase METTL3 promotes the stemness and malignant progression of breast cancer by mediating m⁶A modification on SOX2[J]. J BUON, 2021, 26(2):444-449.
31	Li Z, Yang HY, Dai XY, et al. CircMETTL3, upregulated in a m⁶A-dependent manner, promotes breast cancer progression[J]. Int J Biol Sci, 2021, 17(5):1178-1190.
32	Ruan HG, Gu WC, Xia W, et al. METTL3 is suppressed by circular RNA circMETTL3/miR-34c-3p signaling and limits the tumor growth and metastasis in triple negative breast cancer[J]. Front Oncol, 2021, 11:778132.doi: 10.3389/fonc.2021.778132.
33	Shi Y, Zheng C, Jin Y, et al. Reduced expression of METTL3 promotes metastasis of triple-negative breast cancer by m⁶A methylation-mediated COL3A1 up-regulation[J]. Front Oncol, 2020, 10:1126.doi: 10.3389/fonc.2020.01126.
34	Guan Q, Lin H, Miao L, et al. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer[J]. J Hematol Oncol, 2022, 15(1):13.doi: 10.1186/s13045-022-01231-5.
35	Gong PJ, Shao YC, Yang Y, et al. Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer[J]. Front Oncol, 2020, 10:578963.doi: 10.3389/fonc.2020.578963.
36	Zhou H, Yin K, Zhang Y, et al. The RNA m⁶A writer METTL14 in cancers: Roles, structures, and applications[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188609.doi: 10.1016/j.bbcan.2021.188609.
37	Dong XF, Wang Y, Huang BF, et al. Downregulated METTL14 expression correlates with breast cancer tumor grade and molecular classification[J]. Biomed Res Int, 2020, 2020:8823270.doi: 10.1155/2020/8823270.
38	Wu L, Wu D, Ning J, et al. Changes of N6-methyladenosine modulators promote breast cancer progression[J]. BMC Cancer, 2019, 19(1):326. doi: 10.1186/s12885-019-5538-z.
39	Sun T, Wu Z, Wang X, et al. LNC942 promoting METTL14-mediated m⁶A methylation in breast cancer cell proliferation and progression[J]. Oncogene, 2020, 39(31):5358-5372.
40	Wang CQ, Tang CH, Wang Y, et al. Upregulated WTAP expression appears to both promote breast cancer growth and inhibit lymph node metastasis[J]. Sci Rep, 2022, 12(1):1023. doi: 10.1038/s41598-022-05035-y.
41	Qian JY, Gao J, Sun X, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner[J]. Oncogene, 2019, 38(33):6123-6141.
42	Zhang X, Dai XY, Qian JY, et al. SMC1A regulated by KIAA1429 in m⁶A-independent manner promotes EMT progress in breast cancer[J]. Mol Ther Nucleic Acids, 2021, 27:133-146.
43	Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3[J]. Mol Cancer, 2019, 18(1):46. doi: 10.1186/s12943-019-1004-4.
44	Xu Y, Ye S, Zhang N, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer[J]. Cancer Commun (Lond), 2020, 40(10):484-500.
45	Jeschke J, Collignon E, Al Wardi C, et al. Downregulation of the FTO m⁶A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors[J]. Nat Cancer, 2021, 2(6):611-628.
46	Qu J, Yan H, Hou Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential[J]. J Hematol Oncol. 2022 Jan 21;15(1):8.doi: 10.1186/s13045-022-01224-4.
47	Tang B, Yang Y, Kang M, et al. m⁶A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling[J]. Mol Cancer, 2020, 19(1):3. doi: 10.1186/s12943-019-1128-6.
48	Jin D, Guo J, Wu Y, Y et al. m⁶A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC[J]. Mol Cancer, 2020, 19(1):40.doi: 10.1186/s12943-020-01161-1.
49	Fry NJ, Law BA, Ilkayeva OR, et al. N6-methyladenosine contributes to cellular phenotype in a genetically-defined model of breast cancer progression[J]. Oncotarget, 2018, 9(58):31231-31243.
50	Wu L, Wu D, Ning J, et al. Changes of N6-methyladenosine modulators promote breast cancer progression[J]. BMC Cancer, 2019, 19(1):326.doi: 10.1186/s12885-019-5538-z.
51	Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA[J]. Proc Natl Acad Sci U S A, 2016, 113(14):E2047-56.
52	Lan Q, Liu PY, Bell JL, et al. The Emerging roles of RNA m⁶A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance[J]. Cancer Res, 2021, 81(13):3431-3440.
53	Wu H, Feng J, Wu J, et al. Prognostic value of comprehensive typing based on m⁶A and gene cluster in TNBC[J]. J Cancer Res Clin Oncol, 2022. doi: 10.1007/s00432-022-04345-y.
54	Kim HY, Ha Thi HT, et al. IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor[J]. Cancer Lett, 2018, 415:30-39.
55	Song X, Chen B, Liang Y, et al. CircEIF3H-IGF2BP2-HuR scaffold complex promotes TNBC progression via stabilizing HSPD1/RBM8A/G3BP1 mRNA[J]. Cell Death Discov, 2022, 8(1):261.doi: 10.1038/s41420-022-01055-9.
56	Sui L, Sanders A, Jiang WG, et al. Deregulated molecules and pathways in the predisposition and dissemination of breast cancer cells to bone[J]. Comput Struct Biotechnol J, 2022, 20:2745-2758.
57	Chang G, Shi L, Ye Y, et al. YTHDF3 induces the translation of m⁶A-enriched gene transcripts to promote breast cancer brain metastasis[J]. Cancer Cell, 2020, 38(6):857-871.e7.
58	Lin Y, Jin X, Nie Q, et al. YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m⁶A-dependent manner[J]. Ann Transl Med, 2022, 10(2):83.doi: 10.21037/atm-21-6857.
59	Tan B, Zhou K, Liu W, et al. RNA N6 -methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer[J]. Theranostics, 2022, 12(13):5727-5743.
60	Dieci MV, Miglietta F, Griguolo G, et al. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors[J]. Cancer Treat Rev, 2020, 88:102064.doi: 10.1016/j.ctrv.2020.102064.
61	Chen H, Yu Y, Yang M, et al. YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner[J]. Cell Biosci, 2022, 12(1):19.doi: 10.1186/s13578-022-00759-w.
62	Yao X, Li W, Li L, et al. YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis[J]. Cell Death Dis, 2022, 13(3):258.doi: 10.1038/s41419-022-04711-1.
63	Huang H, Weng H, Chen J. m⁶A modification in coding and non-coding RNAs: Roles and therapeutic implications in cancer[J]. Cancer Cell, 2020, 37(3):270-288.
64	Lv W, Wang Y, Zhao C, et al. Identification and Validation of m⁶A-related lncRNA signature as potential predictive biomarkers in breast cancer[J]. Front Oncol, 2021, 11:745719.doi: 10.3389/fonc.2021.745719.
65	Shi W, Tang Y, Lu J, et al. MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification[J]. Cell Biosci, 2022, 12(1):38. doi: 10.1186/s13578-022-00772-z.
66	Geuens T, Bouhy D, Timmerman V. The hnRNP family: insights into their role in health and disease[J]. Hum Genet, 2016, 135(8):851-867.
67	Liu N, Dai Q, Zheng G, et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions[J]. Nature, 2015, 518(7540):560-564.
68	Zhou KI, Shi H, Lyu R, et al. Regulation of co-transcriptional pre-mRNA splicing by m⁶A through the low-complexity protein hnRNPG[J]. Mol Cell, 2019, 76(1):70-81.e9.
69	Alarcón CR, Goodarzi H, Lee H, et al. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events[J]. Cell, 2015, 162(6):1299-1308.
70	Hwang SJ, Seol HJ, Park YM, et al. MicroRNA-146a suppresses metastatic activity in brain metastasis[J]. Mol Cells, 2012, 34(3):329-334.
71	Wang S, Zou X, Chen Y, et al. Effect of N6-methyladenosine regulators on progression and prognosis of triple-negative breast cancer[J]. Front Genet, 2021, 11:580036.doi: 10.3389/fgene.2020.580036.
72	Lv W, Tan Y, Xiong M, et al. Analysis and validation of m⁶A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression[J]. J Transl Med, 2021, 19(1):527. doi: 10.1186/s12967-021-03196-4.
73	Moran-Jones K, Grindlay J, Jones M, et al. hnRNP A2 regulates alternative mRNA splicing of TP53INP2 to control invasive cell migration[J]. Cancer Res, 2009, 69(24):9219-9227.
74	Zhu S, Hou J, Gao H, et al. SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses[J]. Mol Cell, 2023, 83(4):539-555.e7.
75	Stockley J, Villasevil ME, Nixon C, et al. The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer[J]. RNA Biol, 2014, 11(6):755-765.
76	Liu Y, Li H, Liu F, et al. Heterogeneous nuclear ribonucleoprotein A2/B1 is a negative regulator of human breast cancer metastasis by maintaining the balance of multiple genes and pathways[J]. EBio Medicine, 2020, 51:102583. doi: 10.1016/j.ebiom.2019.11.044.
77	Yang B, Wang JQ, Tan Y, et al. RNA methylation and cancer treatment[J]. Pharmacol Res, 2021, 174:105937.doi: 10.1016/j.phrs.2021.105937.
78	Chen B, Ye F, Yu L, et al. Development of cell-active N6-methyladenosine RNA demethylase FTO inhibitor[J]. J Am Chem Soc, 2012, 134(43):17963-17971.
79	Huang Y, Yan J, Li Q, et al. Meclofenamic acid selectively inhibits FTO demethylation of m⁶A over ALKBH5[J]. Nucleic Acids Res, 2015, 43(1):373-384.
80	Selberg S, Seli N, Kankuri E, et al. Rational design of novel anticancer small-molecule RNA m⁶A demethylase ALKBH5 inhibitors[J]. ACS Omega, 2021, 6(20):13310-13320.
81	Qu J, Yan H, Hou Y, et al. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential[J]. J Hematol Oncol, 2022, 15(1):8.doi: 10.1186/s13045-022-01224-4.
82	Moshitch-Moshkovitz S, Dominissini D, Rechavi G. The epitranscriptome toolbox[J]. Cell, 2022, 185(5):764-776.

RNA m⁶A甲基化修饰组分	乳腺癌组织中表达水平	乳腺癌转移中的作用	调控的靶基因	参考文献
RNA m⁶A"写入蛋白"
METTL3	高	促进转移	MALAT1、KRT7、SOX2	[26，27，28，29，30]
	低	抑制转移	COL3A1	[33]
METTL14	低	抑制转移	未知	[36，37，38]
	高	促进转移	CXCR4	[39]
WTAP	高	抑制转移	未知	[40]
KIAA1429（VIRMA）	高	促进转移	SMC1A	[41，42]
RNA m⁶A"擦除蛋白"
FTO	高	促进转移	BNIP3、miR-181b-3p	[43，44]
	低	抑制转移	APC2、AXIN1	[45]
ALKBH5	高	促进转移	NANOG	[49，50，51]
RNA m⁶A"解读蛋白"
YTHDC1	高	促进转移	SMAD3	[59]
YTHDC2	未知	未知	未知	-
YTHDF1	高	促进转移	FOXM1、PKM2	[61，62]
YTHDF2	低	抑制转移	未知	[56]
YTHDF3	高	促进转移	ST6GALNAC5、ZEB1	[57，58]
IGF2BP1	高	促进转移	lncRNA MIR210HG	[65]
IGF2BP2	高	促进转移	HSPD1、RBM8A、G3BP1	[55]
IGF2BP3	高	促进转移	PR	[54]
hnRNPC	高	促进转移	未知	[70，71，72]
hnRNPA2B1	低	抑制转移	PFN2	[76]

RNA m⁶A甲基化修饰组分	乳腺癌组织中表达水平	乳腺癌转移中的作用	调控的靶基因	参考文献
RNA m⁶A"写入蛋白"
METTL3	高	促进转移	MALAT1、KRT7、SOX2	[26，27，28，29，30]
	低	抑制转移	COL3A1	[33]
METTL14	低	抑制转移	未知	[36，37，38]
	高	促进转移	CXCR4	[39]
WTAP	高	抑制转移	未知	[40]
KIAA1429（VIRMA）	高	促进转移	SMC1A	[41，42]
RNA m⁶A"擦除蛋白"
FTO	高	促进转移	BNIP3、miR-181b-3p	[43，44]
	低	抑制转移	APC2、AXIN1	[45]
ALKBH5	高	促进转移	NANOG	[49，50，51]
RNA m⁶A"解读蛋白"
YTHDC1	高	促进转移	SMAD3	[59]
YTHDC2	未知	未知	未知	-
YTHDF1	高	促进转移	FOXM1、PKM2	[61，62]
YTHDF2	低	抑制转移	未知	[56]
YTHDF3	高	促进转移	ST6GALNAC5、ZEB1	[57，58]
IGF2BP1	高	促进转移	lncRNA MIR210HG	[65]
IGF2BP2	高	促进转移	HSPD1、RBM8A、G3BP1	[55]
IGF2BP3	高	促进转移	PR	[54]
hnRNPC	高	促进转移	未知	[70，71，72]
hnRNPA2B1	低	抑制转移	PFN2	[76]

[1]	Hua Shao, Ziyue Na, Hui Jing, Bo Li, Qiucheng Wang, Wen Cheng. Value of preoperative percutaneous contrast-enhanced ultrasound in diagnosis of axillary sentinel lymph node metastasis and burden in breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 849-853.
[2]	Xu Zhang, Jianping Xu, Dongming Su, Caifen Wang, Dali Wang, Wenzhi Zhang. Contrast-enhanced ultrasound features of male breast masses [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(08): 854-859.
[3]	Meiwu Zhang, Shuyi Lyu, Xiaoxiang Fan, Luhui Zhuang, Yuqin Qiu, Baisong Zhang, Yan Zhang. Clinical value of ultrasound-guided aspiration combined with hypertonic glucose flushing in treatment of postoperative subcutaneous effusion in patients with breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(03): 327-331.
[4]	bing Feng, Qiuguo Zou, Zhenbo Liang, Yanming Lu, Yi Zeng, Shumiao Wu. Clinical study of ultrasonic signs and molecular biological indicators of senile non-specific invasive breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 48-51.
[5]	Yansong Li, Huimin Feng, Mingchao Liu, Zepeng Liu, Qiuxia Jiang. Expression and clinical significance of STIP1 in triple negative breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 52-56.
[6]	Xiaoyan Wang, You Xiao, Ge Xiao, Zhenquan Wang. CT characteristics and risk factors of lung metastasis in elderly patients with colorectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(05): 506-509.
[7]	Jia Wang, Baoliang Guo, Shan Wang, Dianlong Zhang, Mijia Wang, Tianyang Zhou, Jianguo Zhang, Feng Jin. Interpretation of clinical practice guidelines for diagnosis and treatment of de novo stage Ⅳ breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(03): 250-254.
[8]	Chenglu Huang, Fei Liao, Xianping Liu, Zhiqiang Wang. Relationship between overexpression of serum exosomal has_circ_0060937 and metastasis and poor prognosis of NSCLC [J]. Chinese Journal of Lung Diseases(Electronic Edition), 2023, 16(04): 490-494.
[9]	Ruixue Yue, Lingxin Kong, Xin Hao, Jinqiang Yang, Meng Han, Guozhong Cui, Jianjun Wang, Zhisheng Zhang, Fanting Kong, Wei Zhang, Wenbo He, Xianqiao Li, Xinping Zhou, Donghong Xu, Chongzhu Hu. HER2 protein expression levels predict efficacy of neoadjuvant therapy in breast cancer: A real-world study [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 765-770.
[10]	Fei Liu, Yingxin Wang, Xing Ma, Ling Xin, Yuanjia Cheng, Qian Liu, Yue Wang, Junjun Zhang. Different conductive media for intracavitary electrocardiogram-guided arm port implantation among breast cancer patients: a randomized controlled trial [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 760-764.
[11]	Qing Chen, Kejin Wu. Interpretation of basic contents of Clinical Practice China Guidelines for Breast Cancer during Pregnancy and Lactation (2022 edition) [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1050-1053.
[12]	Yilin Xu, Hong Lu, Xuejing Liu, Yujuan Hao, Ziling Yu, Ying Zhu. Value of imaging progress in precise axillary treatment of breast cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1054-1061.
[13]	Fan Yang, Hong Zhang, Jiay Li, Ling Xin, Hongyu Xiang, Qian Liu, Yuanjia Cheng, Jingming Ye, Xuening Duan, Yinhua Liu, Ling Xu, Shuang Zhang. Characteristics of CK5/6 expression in early triple-negative breast cancer: correlation with prognosis and efficacy of neoadjuvant chemotherapy [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1081-1088.
[14]	Exian Mou, Hao Wang, Li Xia, Juan Li, Shiyan Zeng, Miao Yu, Junjie Li, Jia Xu, Purong Zhang, Man Lu, Hui Li, Shiwei Liu. Contrast-enhanced ultrasonography combined with blue dye for sentinel lymph node biopsy in neoadjuvant-treated HER2-positive or triple-negative breast cancer with initially biopsy-proven nodal metastasis [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(11): 1068-1074.
[15]	Zeyu Cai, Huimin Lan, Ting Yu, Hui Luo. The study based on Ti₃C₂ loaded with doxorubicin and combined with photothermal therapy for inhibiting the proliferation of breast cancer cells [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(02): 140-145.

Please choose a citation manager

Content to export

Research progress in the role of dysregulated RNA m⁶A modification in breast cancer metastasis

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

Figures/Tables 3

References 82

Related Articles 15

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export